Low ratio of n3:n6 fatty acids correlates with CAD progression

Low ratio of n3:n6 fatty acids correlates with CAD progression
For statin-treated patients with coronary artery disease, decreases in the ratio of serum n-3 to n-6 polyunsaturated fatty acids correlate with atherosclerosis progression, according to research published in the Jan. 1 issue of The American Journal of Cardiology.

(HealthDay)—For statin-treated patients with coronary artery disease, decreases in the ratio of serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) correlate with atherosclerosis progression, according to research published in the Jan. 1 issue of The American Journal of Cardiology.

Tsuyoshi Nozue, M.D., of the Yokohama Sakae Kyosai Hospital in Japan, and colleagues evaluated the effects of serum n-3 to n-6 PUFA ratios on in 101 statin-treated patients with coronary artery disease who were evaluated using virtual histology ultrasound. The patients were assessed at the time of percutaneous coronary intervention and after eight months of statin therapy.

At follow-up, the researchers found that 46 percent of patients showed atheroma progression and 54 percent exhibited atheroma regression. There were significant negative correlations seen for the change in plaque volume and in the change in fibrous component volume with the changes in the ratios of eicosapentaenoic acid (EPA)/arachidonic acid (AA), docosahexaenoic acid (DHA)/AA, and EPA+DHA/AA. The change in EPA+DPA/AA ratio was a significant predictor of the percentage change in both plaque volume and fibrous component volume in multivariate analysis.

"In conclusion, decreases in serum n-3 to n-6 polyunsaturated fatty acid ratios are associated with progression in coronary atherosclerosis evaluated using virtual histology intravascular ultrasound in statin-treated patients with ," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Drug may reduce coronary artery plaque

Oct 12, 2008

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat ...

Recommended for you

First expert consensus on ventricular arrhythmias published

3 hours ago

The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from ...

'Face time' for the heart diagnoses cardiac disease

22 hours ago

To the careful observer, a person's face has long provided insight into what is going on beneath the surface. Now, with the assistance of a web camera and software algorithms, the face can also reveal whether or not an individual ...

User comments